Retrieve available abstracts of 36 articles: HTML format
Single Articles
June 2025
MAMOUNAS EP, Bandos H, White JR, Julian TB, et al Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
N Engl J Med. 2025;392:2113-2124. PubMedAbstract available
PARTRIDGE AH Menopausal Symptom Management in Breast Cancer Survivors - A Promising New
Option.
N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMe2506475. PubMed
CARDOSO F, Parke S, Brennan DJ, Briggs P, et al Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2415566. PubMedAbstract available
BIDARD FC, Mayer EL, Park YH, Janni W, et al First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502929. PubMedAbstract available
May 2025
CAMPONE M, De Laurentiis M, Jhaveri K, Hu X, et al Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2505725. PubMedAbstract available
JHAVERI KL, Im SA, Saura C, Loibl S, et al Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2501796. PubMedAbstract available
March 2025
SCHMID P, Zhou X, Dent R Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Reply.
N Engl J Med. 2025;392:1142. PubMed
SORSCHER S Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
N Engl J Med. 2025;392:1141-1142. PubMed
SUN R, Seibert TM, Wei LJ Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
N Engl J Med. 2025;392:1141. PubMed
NEVEN P, Floris G, Desmedt C Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
N Engl J Med. 2025;392:1140-1141. PubMed
February 2025
BARDIA A, Schwaederle M, Curigliano G Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply.
N Engl J Med. 2025;392:830-831. PubMed
CONFORTI F, Oriecuia C, Pala L Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
N Engl J Med. 2025;392:830. PubMed
HUANG R, Chen M, Shi Y Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
N Engl J Med. 2025;392:829-830. PubMed
WOLFF AC, McShane LM, Allison KH Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.
N Engl J Med. 2025;392:829. PubMed
January 2025
TURNER NC, Thanopoulou E, Jhaveri KL Inavolisib Therapy in Advanced Breast Cancer. Reply.
N Engl J Med. 2025;392:310-311. PubMed
IBRAHEEM AF, Nguyen R, Gadi VK Inavolisib Therapy in Advanced Breast Cancer.
N Engl J Med. 2025;392:310. PubMed
GEYER CE JR, Untch M, Huang CS, Mano MS, et al Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
N Engl J Med. 2025;392:249-257. PubMedAbstract available
December 2024
MORROW M Sentinel-Lymph-Node Biopsy in Early-Stage Breast Cancer - Is It Obsolete?
N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMe2414899. PubMed
REIMER T, Stachs A, Veselinovic K, Kuhn T, et al Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMoa2412063. PubMedAbstract available
JHAVERI KL, Neven P, Casalnuovo ML, Kim SB, et al Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
N Engl J Med. 2024 Dec 11. doi: 10.1056/NEJMoa2410858. PubMedAbstract available
November 2024
BURSTEIN HJ Immunotherapy for Early-Stage Triple-Negative Breast Cancer.
N Engl J Med. 2024;391:2048-2049. PubMed
October 2024
GRADISHAR WJ Improving the Outcome of Bad-Acting Hormone Receptor-Positive Breast Cancer.
N Engl J Med. 2024;391:1644-1647. PubMed
TURNER NC, Im SA, Saura C, Juric D, et al Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
N Engl J Med. 2024;391:1584-1596. PubMedAbstract available
September 2024
RUBIN EJ, Yeku OO, Morrissey S NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple-
Negative Breast Cancer.
N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411492. PubMed
RUBIN EJ, Yeku OO, Morrissey S NEJM at ESMO - Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic
Breast Cancer.
N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411488. PubMed
SCHMID P, Cortes J, Dent R, McArthur H, et al Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2409932. PubMedAbstract available
BARDIA A, Hu X, Dent R, Yonemori K, et al Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407086. PubMedAbstract available
August 2024
WANDER SA, Thai JN, Wirth LJ, Soto DE, et al Case 26-2024: A 59-Year-Old Woman with Aphasia, Anemia, and a Breast Mass.
N Engl J Med. 2024;391:747-757. PubMed
June 2024
SLAMON D, Yardley DA, Hortobagyi G Ribociclib plus Endocrine Therapy in Early Breast Cancer. Reply.
N Engl J Med. 2024;390:2221-2222. PubMed
TANNOCK IF, Meirson T, Fojo A Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med. 2024;390:2220-2221. PubMed
LI Q, Cai Y, Li J Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med. 2024;390:2220. PubMed
TU H, Zhang Y, You Z Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med. 2024;390:2219-2220. PubMed
VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
N Engl J Med. 2024;390:2011-2022. PubMed
April 2024
DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
N Engl J Med. 2024;390:1163-1175. PubMedAbstract available
MCGUIRE KP Axillary Dissection - The Bell Tolls for Thee.
N Engl J Med. 2024;390:1231-1232. PubMed
March 2024
SLAMON D, Lipatov O, Nowecki Z, McAndrew N, et al Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med. 2024;390:1080-1091. PubMedAbstract available